Global investment firm KKR has closed its previously announced investment in Biosynth Carbosynth, an life sciences reagents, custom synthesis and manufacturing services company, as well as Biosynth Carbosynth’s acquisition of vivitide, a global provider of custom peptides and antibodies for the life sciences and biotech industry.
Existing vivitide owner Ampersand Capital Partners will roll over its entire stake and become a substantial minority shareholder of the combined entity. Together, KKR and Ampersand plan to accelerate the company’s geographic expansion, broaden its capabilities, and expand its product portfolio.
KKR invested in Biosynth Carbosynth through KKR Health Care Strategic Growth Fund II, a USD4.0 billion fund focused on investing in high-growth health care companies for which KKR can be a unique partner in helping companies reach scale.
Read more: Private Equity Wire
